Nasus Pharma to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Nasus Pharma (NYSE: NSRX) announced management will present at three investor conferences in late February and March 2026, with CEO Dan Teleman as the company speaker.
Events: Oppenheimer Healthcare Life Sciences (Feb 25, virtual), BIO Investment & Growth Summit (Mar 2, Miami), Citizens Life Sciences (Mar 11, Miami). Management is available for one-on-one meetings.
Positive
- None.
Negative
- None.
News Market Reaction – NSRX
In the Feb 20 session, NSRX gained 18.00%, reflecting a significant positive market reaction. Argus tracked a peak move of +4.0% during that session. Argus tracked a trough of -19.8% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences in February and March.
Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Date and time: February 25, 2026, 1:20 p.m. ET
- Location: Virtual (register here: https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/KoYPJS8x3zqMuXPHfEHoSY)
- Format: Company presentation
- Speaker: Dan Teleman, Chief Executive Officer
BIO Investment & Growth Summit
- Date and time: March 2, 2026, 10:15 a.m. ET
- Location: Miami, FL
- Format: Company presentation
- Speaker: Dan Teleman, Chief Executive Officer
Citizens Life Sciences Conference
- Date and time: March 11, 2026, 3:25 p.m. ET
- Location: Miami, FL
- Format: Company presentation
- Speaker: Dan Teleman, Chief Executive Officer
Nasus management will be available for one-on-one meetings during the conferences. Interested parties should contact their conference representative to arrange a meeting.
About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’ intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus’ proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.
Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com
Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
